Advances in HIV-1 Vaccine Development

Gao, Yong; McKay, Paul F.; Mann, J. Adin

doi:10.3390/v10040167

Cited by 56 publications

(56 citation statements)

References 145 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason is that many microbial pathogens, such as HIV (human immunodeficiency virus), HCV (hepatitis C virus) and HSV (herpes simplex virus), are showing an elusive or ever-changing immunogenic feature on their appearance to continuously challenge the currently available vaccine strategies while dismantling a variety of potential arsenals. Meanwhile, some pathogens, such as Ebola virus and SARS virus (severe acute respiratory syndrome virus), may emerge abruptly in an uncertain place to make a ravage in people and then disappear before an effective strategy having been drawn up for the trial of battling them, leaving even no trace as a hint for developing an efficacious product able to tame them [3,4]. Nevertheless, the past few decades have witnessed a range of lethal infectious pathogens, such as smallpox, HPV, HBV and VZV (varicella zoster virus), that have been, or nearly, conquered by the newly developed medications including, especially, vaccines [5,6].…”

Section: Introductionmentioning

confidence: 99%

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Wang

Chen

Wang

2019

Journal of Controlled Release

228

155

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Wang

Chen

Wang

2019

Journal of Controlled Release

228

155

View full text Add to dashboard Cite

“…Vaccination is an extremely important public health measure that has demonstrated prophylactic and therapeutic utility against many infectious diseases,1–3 and impacted some forms of cancer 4. In the past decade, advances in material engineering have allowed for the development and study of a new generation of nanoparticle vaccines 5–7.…”

Section: Introductionmentioning

confidence: 99%

In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure‐Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity

Wise

Chokkalingam

et al. 2020

Advanced Science

View full text Add to dashboard Cite

Nanotechnologies are considered to be of growing importance to the vaccine field. Through decoration of immunogens on multivalent nanoparticles, designed nanovaccines can elicit improved humoral immunity. However, significant practical and monetary challenges in large‐scale production of nanovaccines have impeded their widespread clinical translation. Here, an alternative approach is illustrated integrating computational protein modeling and adaptive electroporation‐mediated synthetic DNA delivery, thus enabling direct in vivo production of nanovaccines. DNA‐launched nanoparticles are demonstrated displaying an HIV immunogen spontaneously self‐assembled in vivo. DNA‐launched nanovaccines induce stronger humoral responses than their monomeric counterparts in both mice and guinea pigs, and uniquely elicit CD8+ effector T‐cell immunity as compared to recombinant protein nanovaccines. Improvements in vaccine responses recapitulate when DNA‐launched nanovaccines with alternative scaffolds and decorated antigen are designed and evaluated. Finally, evaluation of functional immune responses induced by DLnanovaccines demonstrates that, in comparison to control mice or mice immunized with DNA‐encoded hemagglutinin monomer, mice immunized with a DNA‐launched hemagglutinin nanoparticle vaccine fully survive a lethal influenza challenge, and have substantially lower viral load, weight loss, and influenza‐induced lung pathology. Additional study of these next‐generation in vivo‐produced nanovaccines may offer advantages for immunization against multiple disease targets.

show abstract

“…This correlation has been exhibited for the CMV virus but not yet for HIV (Gyurova et al, 2017). Initial vaccines were tested in the Succulent (Gao, McKay, & Mann, 2018;Hsu & O'Connell, 2017). Clade, and ultimately a wide variety in the HIV virus.…”

Section: Hiv Vaccinationmentioning

confidence: 99%

Memory and CAR‐NK cell‐based novel approaches for HIV vaccination and eradication

Mazarzaei

Vafaei²,

Ghasemian

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV) is one of the critical infectious agents with thousands of newly infected people worldwide. High mutational capability and rapid diversification, inhibition of humoral and cellular immune responses, and thus inability for recognition of an immunogenic region in the viral envelope by the immune system are major challenges. Natural killer (NK) cells are multifunctional, playing a key role in the identification and elimination of HIV‐infected cells. These cells identify and eliminate virus‐infected cells in a multilateral manner, such as ligand stress, antibody‐dependent cell cytotoxicity (ADCC), T follicular helper (Tfh), and the activation of most of the stimulatory receptors. Moreover, these cells release cytokines leading to the activation of cytotoxic lymphocytes (CTLs) and dendritic cells (DCs), contributing to efficient viral elimination. Some subsets of NK cells exhibit putatively enhanced effector functions against viruses following vaccination easily expanded and identified by NK cell lines culture. Furthermore, NK cells promote the elimination of HIV‐infected cells which reduce the expression of major histocompatibility complex (MHC) molecules. Memory NK cells have higher functionality and renewable potential. A pioneering strategy to establish an efficacious HIV vaccine would include stimulation of the accumulation and long‐term maintenance of these HIV‐reactive NK cells. CAR‐NK (chimeric antigen receptor‐natural killer) cells‐based antiviral therapies have emerged as novel approaches with the ability of antigen recognition and more advantages than CAR‐T (chimeric antigen receptor‐T) cells. Recent development of induced pluripotent stem cell (iPSC)‐derived NK cells with enhanced activity and efficiency conferred a promising insight into CAR‐NK cell‐based therapies. Therefore, memory and CAR‐NK cells‐based approaches can emerge as novel strategies providing implications for HIV vaccine design and therapy.

show abstract

Advances in HIV-1 Vaccine Development

Cited by 56 publications

References 145 publications

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure‐Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity

Memory and CAR‐NK cell‐based novel approaches for HIV vaccination and eradication

Contact Info

Product

Resources

About